Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Relapsed myeloma reports: CAR-T, bispecific Abs & combinations

Mohamad Mohty • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies CAR-T Carfilzomib Daratumumab Dexamethasone
CANDOR CARTITUDE-1

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his overview of the latest updates for multiple myeloma (MM) in the relapsed setting from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Prof. Mohty specifically discusses CAR-T, bispecific antibodies and new combination regimens.

More from Mohamad Mohty

2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024
4:02
Moving CAR-T therapy into earlier lines of treatment for myeloma and the need for effective bridging
Mohamad Mohty • 15 Feb 2024
4:04
Overcoming challenges in CAR T-cell therapy for multiple myeloma
Mohamad Mohty • 15 Feb 2024

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals